Caffeine in apnoeic Asian neonates: A sparse data analysis

British Journal of Clinical Pharmacology

Volumn 54, Issue 1, 2002, Pages 31-37

  Lee, How Sung ^a   Khoo, Yok Moi ^a   Chirino Barcelo, Yazmin ^b   Tan, Kim Leong ^a   Ong, Dorothy ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Apnoea; Asian neonates; Caffeine; Sparse data analysis

Indexed keywords

CAFFEINE CITRATE;

APNEA; ARTICLE; ASIA; BIOLOGICAL MODEL; BLOOD ANALYSIS; BLOOD SAMPLING; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DIURESIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TOLERABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; INTERMETHOD COMPARISON; MALAYSIA; MALE; NEWBORN; PREDICTION; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

APNEA; ASIA; BODY WEIGHT; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITRATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; STATISTICS;

EID: 0036968805     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01589.x     Document Type: Article

References (18)

1. Daily WJR, Klaus M, Meyer HBP. Apnea in premature infants. Monitoring, incidence, heart rate changes, and an effect of environmental temperature. Pediatrics 1969; 43: 510-518.
2. Alden ER, Mandelbain T, Woodrum DE, Wennberg RP, Parks CR, Hodson A. Morbidity and mortality in infants weighing less than 1000 grams in an intensive care nursery. Pediatrics 1972; 50: 40-49.
3. Aranda JV, Cook CE, Gorman W, et al. Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. J Pediatr 1979; 94: 663-668.
4. Brouard C, Moriette G, Murat I, et al. Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnoea in premature infants. Am J Dis Child 1985; 139: 698-700.
5. Fuglsang G, Nielsen K, Kjoer Nielsen L, Sennels F, Jakobsen P, Thelle T. The effect of caffeine compared with theophylline in the treatment of idiopathic apnea in premature infants. Acta Paediatr Scand 1989; 78: 786-788.
6. Scanlon JEM, Chin KC, Morgan MEI, Durbin GM, Hale KA, Brown SS. Caffeine or theophylline for neonatal apnoea? Arch Dis Child 1992; 76: 425-428.
7. Erenberg A. Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study. Pharmacotherapy 2000; 20: 644-652.
8. Lee TC, Charles B, Steer P, Flenady V, Shearman A. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther 1997; 61: 628-640.
9. Thomson AH, Kerr S, Wright S. Population pharmacokinetics of caffeine in neonates and young infants. Ther Drug Monit 1996; 18: 245-253.
10. Falcao AC, Fernandez de Gatta MM, Delgado Iribarnegaray MF, et al. Population pharmacokinetics of caffeine in premature neonates. Eu J Clin Pharmacol 1997; 52: 211-217.
11. Chirino-Barcelo Y, Ong ML, Tan KL, Lee HS, Abdul Rahman Bin MA. Therapeutic effect of aminophylline and caffeine in the treatment of neonatal apnoea. In Singaporean Babies. Abstract Handbook. 2nd NUH-Faculty of Medicine Annual Scientific Meeting 1998, 102.
12. Gomeni R, Pineau G, Mentre F. Population kinetics and conditional assessment of the optimal dosage regimen using P-PHARM software package. Anticancer Res 1994; 14: 2321-2326.
13. Mentre F, Gomeni R. A two-step iterative algorithm for estimation in nonlinear mixed-effect model with an evaluation in population pharmacokinetics. J Biopharm Statist 1995; 5: 141-158.
14. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-512.
15. Oesterheld JR. A review of developmental aspects of cytochrome P450. J Child Adolesc Psychopharmacol 1998; 8: 161-174.
16. Romagnoli C, De Carolis MP, Muzii U, et al. Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants. Ther Drug Monit 1992; 14: 14-19.
17. Carrillo JA, Christensen M, Ramos SI, et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva and urine. Ther Drug Monit 2000; 22: 409-417.
18. van Warmerdam LJC, ten Bokkel Huinink WW, Maes RAA, Beijnen JH. Limited sampling models for anticancer agents. J Cancer Res Clin Oncol 1994; 20: 427-433.